Wave Life Sciences (NASDAQ: WVE) director reports option exercises and stock sales

Rhea-AI Filing Summary

Wave Life Sciences Ltd. director Christian Henry reported a series of option exercises and share sales in the company’s ordinary shares. On December 8, 2025, he exercised options to buy 42,000 shares at $5.97, 15,000 shares at $3.50, and 30,000 shares at $4.585 per share, all from fully vested options. He then sold 6,445 shares at $12.75, 42,000 shares at $12.75, 15,000 shares at a weighted-average price of $14.07 (with individual trades between $14.00 and $14.14), and 30,000 shares at a weighted-average price of $18.02 (with trades between $18.00 and $18.19). After these transactions, he directly owned 12,700 ordinary shares and retained options for 6,000 shares at $3.50 and 15,000 shares at $4.585. All trades were made under a Rule 10b5-1 trading plan adopted on August 6, 2025.

Insider Trade Summary

Net Seller: 93,445 shares ($1,369,324)

Net Sell 10 txns

Insider HENRY CHRISTIAN O

Role Director

Sold 93,445 shs ($1.37M)

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	42,000	$0.00	--
Exercise	Share Option (right to buy)	15,000	$0.00	--
Exercise	Share Option (right to buy)	30,000	$0.00	--
Sale	Ordinary Shares	6,445	$12.75	$82K
Exercise	Ordinary Shares	42,000	$5.97	$251K
Sale	Ordinary Shares	42,000	$12.75	$536K
Exercise	Ordinary Shares	15,000	$3.50	$53K
Sale	Ordinary Shares	15,000	$14.07	$211K
Exercise	Ordinary Shares	30,000	$4.585	$138K
Sale	Ordinary Shares	30,000	$18.02	$541K

Holdings After Transaction: Share Option (right to buy) — 0 shares (Direct); Ordinary Shares — 12,700 shares (Direct)

Footnotes (1)

1. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025. These share options are fully vested. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.00 to $14.14 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $18.00 to $18.19 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENRY CHRISTIAN O

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	12/08/2025		S(1)		6,445	D	$12.75	12,700	D
Ordinary Shares	12/08/2025		M(1)		42,000	A	$5.97	54,700	D
Ordinary Shares	12/08/2025		S(1)		42,000	D	$12.75	12,700	D
Ordinary Shares	12/08/2025		M(1)		15,000	A	$3.5	27,700	D
Ordinary Shares	12/08/2025		S(1)		15,000	D	$14.07(3)	12,700	D
Ordinary Shares	12/08/2025		M(1)		30,000	A	$4.585	42,700	D
Ordinary Shares	12/08/2025		S(1)		30,000	D	$18.02(4)	12,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$5.97	12/08/2025		M(1)			42,000	(2)	08/16/2026	Ordinary Shares	42,000	$0.00	0	D
Share Option (right to buy)	$3.5	12/08/2025		M(1)			15,000	(2)	08/15/2027	Ordinary Shares	15,000	$0.00	6,000	D
Share Option (right to buy)	$4.585	12/08/2025		M(1)			30,000	(2)	08/07/2028	Ordinary Shares	30,000	$0.00	15,000	D

Explanation of Responses:

1. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.

2. These share options are fully vested.

3. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.00 to $14.14 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

4. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $18.00 to $18.19 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Christian Henry	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Wave Life Sciences (WVE) report in this Form 4?

The report shows director Christian Henry exercised multiple stock options and sold ordinary shares of Wave Life Sciences Ltd. on December 8, 2025, and discloses his updated share and option holdings.

How many Wave Life Sciences (WVE) shares did the director sell and at what prices?

On December 8, 2025, he sold 6,445 shares at $12.75, 42,000 shares at $12.75, 15,000 shares at a weighted-average price of $14.07 (range $14.00–$14.14), and 30,000 shares at a weighted-average price of $18.02 (range $18.00–$18.19).

What stock options did the Wave Life Sciences (WVE) director exercise in this filing?

He exercised options to buy 42,000 ordinary shares at $5.97 per share (expiring August 16, 2026), 15,000 shares at $3.50 (expiring August 15, 2027), and 30,000 shares at $4.585 (expiring August 7, 2028). These options are described as fully vested.

How many Wave Life Sciences (WVE) shares does the director own after these transactions?

Following the reported trades, the director directly owned 12,700 ordinary shares of Wave Life Sciences Ltd..

What stock options remain outstanding for the Wave Life Sciences (WVE) director after the Form 4 transactions?

After exercising options, he held 6,000 remaining options with an exercise price of $3.50 per share and 15,000 options with an exercise price of $4.585 per share.

Were the Wave Life Sciences (WVE) insider trades made under a Rule 10b5-1 plan?

Yes. The option exercises and related sales were effected under a Rule 10b5-1 trading plan that the reporting person adopted on August 6, 2025, as disclosed in the explanation of responses.